End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
33.62 CNY | -2.21% | -3.67% | +2.84% |
May. 07 | Mabwell Announces FDA Grants Orphan Drug Designation to 9MW2821 | CI |
Apr. 29 | Mabwell Bioscience Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.84% | 1.86B | - | ||
+7.40% | 113B | B+ | ||
+11.39% | 106B | B+ | ||
+0.41% | 22.27B | B | ||
-11.91% | 22.22B | B+ | ||
-5.99% | 19.43B | A- | ||
-37.85% | 17.87B | A- | ||
-6.20% | 17.24B | B | ||
+7.17% | 14.29B | C+ | ||
+34.96% | 12.52B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- 688062 Stock
- Ratings Mabwell (Shanghai) Bioscience Co., Ltd.